Payment overview · 2025
General Payments
$735.57
35 reported records · 11 companies
Healthcare provider profile · identity verified
Leonard Wayne Bridges, M.D.
Allopathic & Osteopathic Physicians|General Practice · FORSYTH, MO · NPI 1225162779
Verified facts
What the public records show
CMS Open Payments records show Leonard Wayne Bridges, M.D. received $735.57 in general payments during 2025 across 35 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.59 | 26.7% | 10 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $131.47 | 17.9% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $114.81 | 15.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.76 | 10.0% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.00 | 7.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.71 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.76 | 4.9% | 2 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $27.59 | 3.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.72 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.21 | 2.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.95 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $735.57 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $149.37 | 7 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $131.47 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $101.10 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $90.52 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $73.76 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.00 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $53.88 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.71 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.76 | 2 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $27.59 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 47 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 801 | 133 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 273 | 44 |
| Oxycodone Hcl | Oxycodone Hcl | 269 | 32 |
| Gabapentin | Gabapentin | 265 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 223 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 192 | 77 |
| Lisinopril | Lisinopril | 169 | 57 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 145 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 143 | 111 |
| Pregabalin | Pregabalin | 110 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 35 |
| Metformin Hcl | Metformin Hcl | 104 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 36 |
| Potassium Chloride | Potassium Chloride | 102 | 37 |
| Tramadol Hcl | Tramadol Hcl | 99 | 34 |
| Omeprazole | Omeprazole | 97 | 32 |
| Alprazolam | Alprazolam | 94 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 25 |
| Trazodone Hcl | Trazodone Hcl | 83 | 31 |
| Levofloxacin | Levofloxacin | 78 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 24 |
| Testosterone Cypionate | Testosterone Cypionate | 72 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 18 |
| Montelukast Sodium | Montelukast Sodium | 68 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 23 |
| Furosemide | Furosemide | 66 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Losartan Potassium | Losartan Potassium | 62 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 19 |
| Eliquis | Apixaban | 59 | 15 |
| Sertraline Hcl | Sertraline Hcl | 58 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 11 |
| Simvastatin | Simvastatin | 54 | 18 |
| Baclofen | Baclofen | 50 | 14 |
| Carvedilol | Carvedilol | 50 | 18 |
| Allopurinol | Allopurinol | 48 | 12 |
| Farxiga | Dapagliflozin Propanediol | 47 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 20 |
| Ozempic | Semaglutide | 45 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | 15 |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | 11 |
| Naloxone Hcl | Naloxone Hcl | 38 | 36 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 36 | 36 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Diazepam | Diazepam | 33 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | 13 |
| Vraylar | Cariprazine Hcl | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Prednisone | Prednisone | 12 | 12 |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $735.57 · 35 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, ETERNA, FARXIGA, FREESTYLE LIBRE, JARDIANCE, MOUNJARO, NEXPLANON, NURTEC ODT, Senza, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error